Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 12 of 14

3. Genelux Corp (NASDAQ:GNLX)

Number of Hedge Fund Holders In Q4 2024: 8

Genelux Corp (NASDAQ:GNLX) is a biopharma company making oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

The stock is up significantly so far in 2025 as investors are optimistic about the company’s OnPrime Phase 3 registrational trial in platinum-resistant/refractory ovarian cancer. Results are expected in the second half of 2025.

Also, interim data from the NSCLC (non-small cell lung cancer) trial is expected in mid-2025. Topline results from the Phase 3 OnPrime/GOG-3076 registration trial in platinum-resistant/refractory ovarian cancer (PRROC) are expected in the second half of 2025.

The consensus price target of $18.25 implies 323.43% upside.

GNLX is up 82.63% year-to-date.

Page 12 of 14